Immunotherapy before surgery shows promise for aggressive skin cancer

NCT ID NCT04315701

First seen Nov 20, 2025 · Last updated Apr 29, 2026 · Updated 17 times

Summary

This study tests whether giving the immunotherapy drug cemiplimab before surgery can help shrink high-risk skin cancers that haven't spread far. About 35 adults with certain types of squamous cell skin cancer will receive the drug and then have surgery. The goal is to see if this approach reduces the amount of cancer left behind and improves long-term control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT SKIN SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hoag Memorial Hospital

    Newport Beach, California, 92663, United States

  • Los Angeles County-USC Medical Center

    Los Angeles, California, 90033, United States

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois, 60611, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of Nebraska

    Omaha, Nebraska, 68198, United States

Conditions

Explore the condition pages connected to this study.